This work is licensed under the Creative Commons Attribution 4.0 International License.
Bischof JJ, Presley CJ, Caterino JM. Addressing new diagnostic and treatment challenges associated with a new age of cancer treatment. Ann Emerg Med 2019; 73: 88–90. doi: 10.1016/j.annemergmed.2018.08.421BischofJJPresleyCJCaterinoJMAddressing new diagnostic and treatment challenges associated with a new age of cancer treatmentAnn Emerg Med201973889010.1016/j.annemergmed.2018.08.421Open DOISearch in Google Scholar
Mayer DK, Travers D, Wyss A, Leak A, Waller A. Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina. J Clin Oncol 2011; 29: 2683–8. doi: 10.1200/JCO.2010.34.2816MayerDKTraversDWyssALeakAWallerAWhy do patients with cancer visit emergency departments? Results of a 2008 population study in North CarolinaJ Clin Oncol2011292683810.1200/JCO.2010.34.2816Open DOISearch in Google Scholar
Lewis MA, Hendrickson WA, Moynihan TJ. Oncologic emergencies: pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin 2011; 61: 287–314. doi: 10.3322/caac.20124LewisMAHendricksonWAMoynihanTJOncologic emergencies: pathophysiology, presentation, diagnosis, and treatmentCA Cancer J Clin20116128731410.3322/caac.20124Open DOISearch in Google Scholar
Alahmadi A, Altamimi H, Algarni M. Evaluation of knowledge of immunotherapy toxicities among emergency physicians in Riyadh, Saudi Arabia. Cureus 2022; 14: e30325. doi: 10.7759/cureus.30325AlahmadiAAltamimiHAlgarniMEvaluation of knowledge of immunotherapy toxicities among emergency physicians in Riyadh, Saudi ArabiaCureus202214e3032510.7759/cureus.30325Open DOISearch in Google Scholar
Higdon ML, Higdon JA. Treatment of oncologic emergencies. Am Fam Physician 2006; 74: 1873–80. PMID: 17168344HigdonMLHigdonJATreatment of oncologic emergenciesAm Fam Physician20067418738017168344Search in Google Scholar
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–64. doi: 10.1038/nrc3239PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer2012122526410.1038/nrc3239Open DOISearch in Google Scholar
Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27: 559–74. doi: 10.1093/annonc/mdv623ChampiatSLambotteOBarreauEBelkhirRBerdelouACarbonnelFManagement of immune checkpoint blockade dysimmune toxicities: a collaborative position paperAnn Oncol2016275597410.1093/annonc/mdv623Open DOISearch in Google Scholar
Palaskas N, Lopez-Mattei J, Durand JB, et al. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc 2020; 9: e013757. doi: 10.1161/JAHA.119.013757PalaskasNLopez-MatteiJDurandJBImmune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatmentJ Am Heart Assoc20209e01375710.1161/JAHA.119.013757Open DOISearch in Google Scholar
Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Matthias Endres M, et al. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort study. Eur J Cancer 2022; 175: 224–35. doi: 10.1016/j.ejca.2022.08.009Müller-JensenLZieroldSVersluisJMBoehmerleWHuehnchenPMatthias EndresMCharacteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: a retrospective multicentre cohort studyEur J Cancer20221752243510.1016/j.ejca.2022.08.009Open DOISearch in Google Scholar
Haanen J, Obeid N, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 1217–38. doi: 10.1016/j.annonc.2022.10.001HaanenJObeidNSpainLCarbonnelFWangYRobertCManagement of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnn Oncol20223312173810.1016/j.annonc.2022.10.001Open DOISearch in Google Scholar
Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013; 10: 267–76. doi: 10.1038/nrclinonc.2013.46KochenderferJNRosenbergSATreating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptorsNat Rev Clin Oncol2013102677610.1038/nrclinonc.2013.46Open DOISearch in Google Scholar
Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol 2021; 18: 71–84. doi: 10.1038/s41571-020-0427-6MikkilineniLKochenderferJNCAR T cell therapies for patients with multiple myelomaNat Rev Clin Oncol202118718410.1038/s41571-020-0427-6Open DOISearch in Google Scholar
Kish J, Liu R, Pfeffer D, Vennam S, Lussier C, Nayak P. Real-world duration of hospitalization for CAR-T treatment: U.S. patient experience in multiple hematologic malignancies. [abstract]. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). J Clin Oncol 2023; 41(Suppl S): e18896. doi: Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol 2020; 17: 418–34. doi: 10.1038/s41571-020-0347-5KishJLiuRPfefferDVennamSLussierCNayakPReal-world duration of hospitalization for CAR-T treatment: U.S. patient experience in multiple hematologic malignancies. [abstract]. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)J Clin Oncol202341Suppl Se18896doi: Goebeler ME, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol 2020; 17: 418–34.10.1038/s41571-020-0347-5Open DOISearch in Google Scholar
Ball K, Dovedi SJ, Vajjah P, Phipps A. Strategies for clinical dose optimization of T cell-engaging therapies in oncology. mAbs 2023; 15: 2181016. doi: 10.1080/19420862.2023.2181016BallKDovediSJVajjahPPhippsAStrategies for clinical dose optimization of T cell-engaging therapies in oncologymAbs202315218101610.1080/19420862.2023.2181016Open DOISearch in Google Scholar
Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med 2020; 383: 2255–73. doi: 10.1056/NEJMra2026131FajgenbaumDCJuneCHCytokine stormN Engl J Med202038322557310.1056/NEJMra2026131Open DOISearch in Google Scholar
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019; 25: 625–38. doi: 10.1016/j.bbmt.2018.12.758LeeDWSantomassoBDLockeFLGhobadiATurtleCJBrudnoJNASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cellsBiol Blood Marrow Transplant2019256253810.1016/j.bbmt.2018.12.758Open DOISearch in Google Scholar
Hernani R, Benzaquén A, Solan C. Toxicities following CAR-T therapy for hematological malignancies. Cancer Treat Rev 2022: 111: 102479. doi: 10.1016/j.ctrv.2022.102479HernaniRBenzaquénASolanCToxicities following CAR-T therapy for hematological malignanciesCancer Treat Rev202211110247910.1016/j.ctrv.2022.102479Open DOISearch in Google Scholar
Morris EM, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 2022; 22: 85–96. doi: 10.1038/s41577-021-00547-6MorrisEMNeelapuSSGiavridisTSadelainMCytokine release syndrome and associated neurotoxicity in cancer immunotherapyNat Rev Immunol202222859610.1038/s41577-021-00547-6Open DOISearch in Google Scholar
Rejeski K, Subklewe M, Locke FL. Recognizing, defining, and managing CAR-T hematologic toxicities. Hematology Am Soc Hematol Educ Program 2023; 2023: 198–208. doi: 10.1182/hematology.2023000472RejeskiKSubkleweMLockeFLRecognizing, defining, and managing CAR-T hematologic toxicitiesHematology Am Soc Hematol Educ Program2023202319820810.1182/hematology.2023000472Open DOISearch in Google Scholar
Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 2018; 15: 47–62. doi: 10.1038/nrclinonc.2017.148.NeelapuSSTummalaSKebriaeiPWierdaWGutierrezCLockeFLChimeric antigen receptor T-cell therapy - assessment and management of toxicitiesNat Rev Clin Oncol201815476210.1038/nrclinonc.2017.148Open DOISearch in Google Scholar
Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO Guideline. J Clin Oncol 2021; 39: 3978–92. doi: 10.1200/JCO.21.01992SantomassoBDNastoupilLJAdkinsSLacchettiCSchneiderBJAnadkatMManagement of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO GuidelineJ Clin Oncol20213939789210.1200/JCO.21.01992Open DOISearch in Google Scholar
Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv 2020; 4: 3123–7. doi: 10.1182/bloodadvances.2020002328StratiPAhmedSKebriaeiPNastoupilLJClaussenCMWatsonGClinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphomaBlood Adv202043123710.1182/bloodadvances.2020002328Open DOISearch in Google Scholar
Rosée PL, Horne AC, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019; 133: 2465–77. doi: 10.1182/blood.2018894618RoséePLHorneACHinesMvon Bahr GreenwoodTMachowiczRBerlinerNRecommendations for the management of hemophagocytic lymphohistiocytosis in adultsBlood201913324657710.1182/blood.2018894618Open DOISearch in Google Scholar
Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 2021; 18: 327–44. doi: 10.1038/s41571-021-00470-8DragoJZModiSChandarlapatySUnlocking the potential of antibody-drug conjugates for cancer therapyNat Rev Clin Oncol2021183274410.1038/s41571-021-00470-8Open DOISearch in Google Scholar
Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol 2024; 21: 203–23. doi: 10.1038/s41571-023-00850-2TsuchikamaKAnamiYHaSYYYamazakiCMExploring the next generation of antibody-drug conjugatesNat Rev Clin Oncol2024212032310.1038/s41571-023-00850-2Open DOISearch in Google Scholar
Tarantino P, Ricciuti B, Pradhan SM. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol 2023; 20: 558–76. doi: 10.1038/s41571-023-00783-wTarantinoPRicciutiBPradhanSMOptimizing the safety of antibody-drug conjugates for patients with solid tumoursNat Rev Clin Oncol2023205587610.1038/s41571-023-00783-wOpen DOISearch in Google Scholar
Rugo HS, Crossno CL, Gesthalter YB, Kelley K, Moore HB, Rimawi MF, et al. Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer. JCO Oncol Pract 2023; 19: 539–46. doi: 10.1200/OP.22.00480RugoHSCrossnoCLGesthalterYBKelleyKMooreHBRimawiMFReal-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancerJCO Oncol Pract2023195394610.1200/OP.22.00480Open DOISearch in Google Scholar
Lacouture ME, Patel AB, Rosenberg JE, Peter H O’Donnell. Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin. Oncologist 2022; 27: e223–32. doi: 10.1093/oncolo/oyac001LacoutureMEPatelABRosenbergJEPeterHO’DonnellManagement of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotinOncologist202227e2233210.1093/oncolo/oyac001Open DOISearch in Google Scholar
Cooksley T, Rice T. Emergency oncology: development, current position and future direction in the USA and UK. Support Care Cancer 2017; 25: 3–7. doi: 10.1007/s00520-016-3470-1CooksleyTRiceTEmergency oncology: development, current position and future direction in the USA and UKSupport Care Cancer2017253710.1007/s00520-016-3470-1Open DOISearch in Google Scholar